



Phone: 1-833-FOS-FAST
 Fax: 844-504-3278
 Website: www.FOSRXFAST.com

Maryland Office
 217 Glenn Street Ste 300
 Cumberland, MD 21502

Louisiana Office
 3131 N. 1-10 Service Rd. E., Ste. 202
 Metairie, LA 70002

Texas Office
 2600 W. Pleasant Run RD STE 1-173
 Lancaster, TX 75146

Prescribing Practitioner:	NPI:
Supervising Physician:	NPI:
Address:	Tax ID:
Office:	Fax:
Contact:	This prescription form is to be sent and received via fax.

Dermatology Enrollment Form: Humira

Faxed prescriptions will only be accepted from a prescribing practitioner. Patients must bring an original prescription to the pharmacy, and cannot fax these referral forms to FOSRX/FAST.


PATIENT INFORMATION			
Name:	M <input type="checkbox"/> F <input type="checkbox"/>	DOB:	SS#:
Street:	City:	State:	Zip:
Telephone:	Alt. Tel:	English <input type="checkbox"/> Spanish <input type="checkbox"/> Other:	Wt: Ht:

PRESCRIPTION	
New <input type="checkbox"/> Refill <input type="checkbox"/>	Ship by: ___/___/___ Ship to: <input type="checkbox"/> Patient's Home <input type="checkbox"/> Doctor's Office <input type="checkbox"/> Other: _____

Drug	Directions and Quantity	Refills
Humira® Citrate Free	<input type="checkbox"/> Psoriasis Starter Kit <input type="checkbox"/> Pen <input type="checkbox"/> Pre-filled Syringe <input type="checkbox"/> INITIAL: Inject 80 mg SQ on Day 1, 40 mg on Day 8, then 40 mg every other week (Quantity: 3) <input type="checkbox"/> MAINTENANCE: Inject 40 mg SQ every other week (Quantity: 2)	
	<input type="checkbox"/> HS Starter Kit <input type="checkbox"/> Pen <input type="checkbox"/> Pre-filled Syringe ADULT: <input type="checkbox"/> INITIAL: Inject 160 mg SQ on Day 1, 80 mg on Day 15, then 40 mg once a week starting day 29 (Quantity: 3) <input type="checkbox"/> MAINTENANCE: Inject 40 mg SQ every week (Quantity: 4)	
	<input type="checkbox"/> Adolescent HS Starter Kit <input type="checkbox"/> Pen <input type="checkbox"/> Pre-filled Syringe ADOLESCENT: **WEIGHT REQUIRED** <input type="checkbox"/> INITIAL: Inject 160 mg SQ on Day 1, 80 mg on Day 15, then 40 mg once a week starting day 29 (Quantity: 3) <input type="checkbox"/> MAINTENANCE: Inject 40 mg SQ every week (Quantity: 4) **Intended for weight > 60 kg/132 lbs**	
Humira®	<input type="checkbox"/> Psoriasis Starter Kit <input type="checkbox"/> Pen <input type="checkbox"/> Pre-filled Syringe <input type="checkbox"/> INITIAL: Inject 80 mg SQ on Day 1, 40 mg on Day 8, then 40 mg every other week (Quantity: 3) <input type="checkbox"/> MAINTENANCE: Inject 40 mg SQ every other week (Quantity: 2)	
	<input type="checkbox"/> HS Starter Kit <input type="checkbox"/> Pen <input type="checkbox"/> Pre-filled Syringe ADULT: <input type="checkbox"/> INITIAL: Inject 160 mg SQ on Day 1, 80 mg on Day 15, then 40 mg once a week starting day 29 (Quantity: 3) <input type="checkbox"/> MAINTENANCE: Inject 40 mg SQ every week (Quantity: 4)	
	<input type="checkbox"/> Adolescent HS Starter Kit <input type="checkbox"/> Pen <input type="checkbox"/> Pre-filled Syringe ADOLESCENT: **WEIGHT REQUIRED** <input type="checkbox"/> INITIAL: Inject 160 mg SQ on Day 1, 80 mg on Day 15, then 40 mg once a week starting day 29 (Quantity: 3) <input type="checkbox"/> MAINTENANCE: Inject 40 mg SQ every week (Quantity: 4) **Intended for weight > 60 kg/132 lbs**	

MEDICAL INFORMATION

***PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY

Previous Therapies: <input type="checkbox"/> Methotrexate <input type="checkbox"/> Soriatane <input type="checkbox"/> Clobetasol <input type="checkbox"/> Hydrocortisone <input type="checkbox"/> Eucrisa <input type="checkbox"/> Stelara <input type="checkbox"/> Enbrel <input type="checkbox"/> _____ <input type="checkbox"/> _____	Tried & Failed (Duration): <input type="checkbox"/> (_____) <input type="checkbox"/> (_____) <input type="checkbox"/> (_____) <input type="checkbox"/> (_____) <input type="checkbox"/> (_____) <input type="checkbox"/> (_____) <input type="checkbox"/> (_____)	Not Tolerated: <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/>	Contraindication: _____ _____ _____ _____ _____	<input type="checkbox"/> Face <input type="checkbox"/> Feet <input type="checkbox"/> Groin <input type="checkbox"/> Hands <input type="checkbox"/> Nails <input type="checkbox"/> Scalp <input type="checkbox"/> Other: _____	
PHOTOTHERAPY <input type="checkbox"/> UVA/UVB <input type="checkbox"/> Patient Cannot Afford	Tried & Failed (Duration): <input type="checkbox"/> (_____)	Not Tolerated: <input type="checkbox"/>	Contraindication: <input type="checkbox"/> Distance from office	Scoring Tool Used <input type="checkbox"/> BSI <input type="checkbox"/> EASI <input type="checkbox"/> SCORAD <input type="checkbox"/> POEM <input type="checkbox"/> ISGA <input type="checkbox"/> % or SCORE _____	Date of Diagnosis: ___/___/___ Allergies: _____ Active TB is ruled out: <input type="checkbox"/> Date: ___/___/___ Hep B ruled out/treated: <input type="checkbox"/> Date: ___/___/___
<input type="checkbox"/> L40.Psoriasis Vulgaris (Plaque Psoriasis) <input type="checkbox"/> L73.2 Hidradenitis suppurativa	<input type="checkbox"/> L40. _____ <input type="checkbox"/> Other: _____				

AMERICAN ACADEMY OF DERMATOLOGY CONSENSUS STATEMENT ON PSORIASIS THERAPIES

Psoriasis is covering greater than 10% body surface area
 Psoriasis is on palms, soles, head & neck, or genitals
 Psoriasis occurs in conjunction with pain, swelling, or stiffness in joints
 Psoriasis patient needs more aggressive therapy due to impact on ability to perform daily activities, employment, or interpersonal relationships

Patient has received pen and injection training
 Physician's office to provide injection training
 FOSRX/FAST to coordinate injection training

PRESCRIBING PRACTITIONER SIGNATURE
 To Prescribing Practitioner: By signing this form and utilizing our services, you are also authorizing FOSRX/FAST to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies and co-pay foundations.

Prescribing Practitioner: _____ Date: _____